Survival outcome of patients with peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) who experience disease progression/relapse remains very poor. A total of 321 patients, newly diagnosed with PTCL-NOS (n = 180) or AITL (n = 141) between 1999 and 2015, were analysed. Failure-free survival (FFS) and overall survival (OS) were calculated from the time of first disease progression (FFS1, OS1), from second disease progression (FFS2, OS2) and from third progression (FFS3, OS3). With a median follow-up duration of 52 months, 240 patients (135 PTCL-NOS, 105 AITL) experienced progression/relapse. In patients with PTCL-NOS, the median durations of FFS1, FFS2 and FFS3 were 3Á1, 2Á5 and 2Á1 months, respectively. In patients with AITL, they were 5Á5, 2Á9 and 2Á3 months, respectively. There was no improvement in FFS1 and OS1 by the time of recurrence during this period (1999-2004, 2005-2009 and 2010-2015). The median FFS after pralatrexate and romidepsin was only 3Á0 and 2Á5 months, respectively. The 5-year OS rates after salvage autologous and allogeneic transplant were 32% and 52%, respectively; while the 5-year OS rates for patients who did not undergo transplant was 10%. Further research for novel therapeutic approaches with higher efficacy and better safety profile are needed.
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphomas that represents 5-10% of all lymphomas in the United States (Morton et al, 2006; Chihara et al, 2014) . The two most common histological subtypes are PTCL, not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL), accounting for 40-50% of cases of all PTCL. Patients with PTCL-NOS and AITL are most commonly treated with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)-like therapy, which is associated with long-term progression-free survival (PFS) of about 30% (Vose et al, 2008; Reimer et al, 2009; Simon et al, 2010) . Young and fit patients may be offered more intensive approaches, including frontline stem cell transplant (SCT) for consolidation of remission, resulting in longer disease control (Reimer et al, 2009; d'Amore et al, 2012) , but for those patients who do not respond to initial therapy or who experience relapse, the prognosis remains poor.
In a report from the British Colombia Cancer Agency, the median PFS and overall survival (OS) after the first recurrence or disease progression were only 3Á1 and 5Á5 months, respectively, without SCT (Mak et al, 2013) . There was only a small difference in the OS between patients who received chemotherapy and those who did not (6Á5 vs. 3Á7 months, respectively). The Swedish Lymphoma Registry also reported survival of patients with PTCL after first relapse/progression (Ellin et al, 2014) . The median OS after relapse or progression in patients who initially responded to first line therapy was 6Á0 months. In this study, patients in these studies were treated for recurrent disease with conventional cytotoxic chemotherapy. Over the last 6 years, the US Food and Drug Administration (FDA) approved four drugs with novel mechanisms of action for the treatment of patients with recurrent PTCL: these included pralatrexate in 2009, brentuximab vedotin (BV) for anaplastic large cell lymphoma (ALCL) in 2011, romidepsin in 2011 and belinostat in 2014. While these drugs are additions to the therapeutic options, response rates were generally less than 30% with the exception of BV for patients with ALCL, and an actual impact on long-term outcome has not been well described. Herein we report the outcome of patients with recurrence of the two most common subtypes of PTCL, which are PTCL-NOS and AITL, treated at The University of Texas MD Anderson Cancer Center. We performed our analysis according to the histology and the number of prior treatment regimens, and sought to assess the impact of new therapeutic options, particularly pralatrexate and romidepsin.
Patients and methods
We analysed the results of 321 consecutive patients with newly diagnosed with PTCL-NOS (N = 180) or AITL (N = 141) between 1999 and 2014. The diagnosis was based on current consensus criteria at the time as summarized by the World Health Organization (Harris et al, 1994; Jaffe et al, 2001; Swerdlow et al, 2008) . Patients with ALCL were excluded from the study due to the huge impact of BV for relapsed/refractory disease. Calculation, scoring and separation of risk groups using the International Prognostic Index (IPI) and the Prognostic Index for PTCL-NOS (PIT) were performed as previously described (The International NonHodgkin's Lymphoma Prognostic Factors Project 1993, Gallamini et al, 2004) . Continuous variables were compared using the Mann-Whitney U-test and categorical variables were compared using the Fisher exact test between the patients with PTCL-NOS and AITL. Response to the treatment was reported according to 1999 response criteria (Cheson et al, 1999) , and according to 2007 revised criteria when a positron emission tomography (PET) scan was performed (Cheson et al, 2007) . Response for patients who underwent SCT was recorded prior to SCT.
Failure-free survival (FFS: progression/relapse of lymphoma or initiation of next therapy or death from treatment-related mortality/myelodysplastic syndrome) and overall survival (OS: death from any cause) from the first progression/relapse (FFS1 and OS1), from the second progression/relapse (FFS2 and OS2) and from the third progression/relapse (FFS3 and OS3) were calculated using the Kaplan-Meier method.
In addition, FFS1 and OS1 were calculated according to three different time periods of progression/relapse (1999-2004, 2005-2009 and 2010-2015) . The OS after SCT was calculated from the date of transplant to death from any cause. Cox proportional hazard regression models were used to evaluate characteristics affecting FFS and OS. Cox proportional hazard model was used to identify the prognostic significance of risk factors for FFS1 and OS1, and dummy variables were used for missing data (Polissar & Diehr, 1982) . The degree of association was described by hazard ratio (HR) with a 95% confidence interval (95% CI). Multivariate analysis was performed using all available variables. All analyses were performed using STATA version 13Á1 (StataCorp LP, College Station, TX, USA), and the significant P-value was defined as <0Á05. The study was performed in accordance with the declaration of Helsinki and approved by the institutional review board of MD Anderson Cancer Center.
Results

Patient characteristics and first-line treatment
First-line chemotherapy regimens included CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone, n = 202), CHOEP (CHOP plus etoposide, n = 15), CEOP (cyclophosphamide, etoposide, vincristine and prednisone, n = 14), hyper-CVAD/MA or hyper-CVIDD/MA hyperfractionated cyclophosphamide, vincristine, dexamethasone and doxorubicin or liposomal doxorubicin alternating with methotrexate and cytarabine: Chihara et al, 2015) (n = 50), alternating triple therapy (Cabanillas et al, 1998) (n = 15), EPOCH (etoposide, prednisolone, vincristine, cyclophosphamide; doxorubicin; Wilson et al, 1993) (n = 8) and others (n = 19). The overall response rate (ORR) to first line therapy was 75% (95% CI: 69-79%) with a complete response (CR) rate of 60% (95% CI: 54-66%). Forty-two patients received consolidative SCT following first-line therapy (auto-SCT n = 39 and allo-SCT n = 3), either in CR (n = 38) or in partial response (n = 4).
With a median follow-up of 55Á5 months, 240 patients (135 PTCL-NOS, 105 AITL) experienced progression/relapse after first-line therapy. Characteristics of patients at the time of first progression/relapse are summarized in Table I . The median age of patients at progression/relapse was 60 years (range, 23-83) . At the time of first progression/relapse, 11%, 36%, 32% and 21% patients were in PIT risk groups 1, 2, 3 and 4, respectively.
Failure-free survival and overall survival post first progression/relapse Second line treatment regimens included ICE (ifosphamide, carboplatin, etoposide, n = 46, nine of whom also received romidepsin with their combination), ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin, n = 26, including one with BV), gemcitabine (n = 25, including 18 with oxaliplatin and two with pralatrexate), single agent pralatrexate (n = 7), single agent romidepsin (n = 8), other investigational drugs (n = 40), other chemotherapy (n = 42) and unknown (treated outside MD Anderson Cancer Center, Survival after Relapse of PTCL ª 2016 John Wiley & Sons Ltd n = 18). Twenty-eight patients did not receive lymphomaspecific treatment because of their poor overall condition. The ORR for second line therapy was 44% (95% CI: 36-51%) with a CR rate of 28% (95% CI: 22-36%). Twenty-five and 15 patients eventually underwent autologous and allogeneic SCT, respectively, after having had an adequate response (per treating physician) to the second line chemotherapy. There were no significant differences in response rate or FFS1 by second line regimen ( Figure S1 ).
Time of second line treatment (1999-2005, 2005-2010 and 2010-2015) did not significantly affect FFS1 and OS1 (Fig 1A,B) . When multivatiate analysis was performed including baseline PIT risk or second PIT risk, response duration to first line therapy (as a continuous variable or <1 year vs >= 1 year), FFS1 and OS1 still remained unaffected by the time of treatment (data not shown).
Third line regimens included ICE (n = 6), ESHAP (n = 15), gemcitabine (n = 15, including 6 with oxaliplatin and 1 with dexamethasone and cisplatin), pralatrexate (n = 5), romidepsin (n = 13, including 2 with alisertib), other investigational drugs (n = 29) and other chemotherapy regimens (n = 29). Forty-one patients did not receive treatment. The ORR for third line therapy was 27% (95% CI: 19-36%) with a CR rate of 13% (95% CI: 7-20%). Fifteen patients received auto-SCT (n = 8) or allo-SCT (n = 7) after responding to the third line therapy. There were no significant differences in FFS2 according to choice of treatment regimen (data not shown).
Fourth line regimens included ICE (n = 4), ESHAP (n = 4), gemcitabine (n = 10, including 6 with oxaliplatin and 2 with ifosfamide and vinorelbine), pralatrexate (n = 5), romidepsin (n = 8), other investigational drugs (n = 6), other chemotherapy (n = 28), and unknown (n = 2). Fortytwo patients did not receive treatment. The ORR for fourth line therapy was 24% (95% CI: 14-36%) with a CR rate of 14% (95% CI: 7-25%). Five patients received auto-SCT (n = 2) or allo-SCT (n = 3) after responding to fourth line therapy. There were no significant differences in FFS3 according to choice of treatment regimen (data not shown).
In patients with PTCL-NOS, the median FFS1 (n=135), FFS2 (n=92) and FFS3 (n=63) were 3Á1, 2Á5 and 2Á1 months, respectively (Fig 2A) : the corresponding median OS1, OS2 and OS3 were 10Á9, 6Á5 and 5Á6 months (Fig 2B) . In patients with AITL, the median FFS1 (n = 105), FFS2 (n = 62) and FFS3 (n = 45) were 5Á5, 2Á9 and 2Á3 months, respectively (Fig 2C) , and median OS1, OS2 and OS3 were 15Á0, 8Á3 and 6Á0 months (Fig 2D) .
The median FFS1 and OS1 for patients who did not proceed to SCT were 4Á0 months (95% CI: 3Á1-4Á7 months) and 9Á2 months (95% CI: 6Á9-11Á8 months), respectively. The median FFS2 and OS2 for those who did not proceed to SCT at any time during the treatment was 2Á5 months (95% CI: 2Á0-3Á1 months) and 5Á5 months (95% CI: 3Á5-7Á4 months), respectively.
Pralatrexate and romidepsin, risk factors after relapse
A total of 56 patients received pralatrexate (total n = 27, as second line therapy n = 10, third line therapy n = 6, fourth and after n = 11) and/or romidepsin (total n = 42, as second line therapy n = 17, third line therapy n = 12, fourth and after n = 13) at some point during salvage therapy. Thirteen patients received both drugs. The ORR for pralatrexate and romidepsin as single agents was 41% (95% CI: 21-64%) and 42% (95% CI: 25-61%), respectively. The CR rates for pralatrexate and romidepsin as single agents were 23% (95% CI: 8-45%) and 24% (95% CI: 11-42%), respectively. All CRs were confirmed by PET scan. Because of the small numbers, there were no significant difference in response between PTCL-NOS and AITL; however only one AITL patient achieved CR with pralatrexate compared to four PTCL-NOS patients. The number of prior regimens had no significant (Table SI) . However, the CR rate from pralatrexate or romidepsin was 0% when used for fifth line therapy or more. The median FFS after pralatrexate and romidepsin as single agents was 3Á0 and 2Á5 months, respectively. The median durations of response in responders after pralatrexate and romidepsin as single agents were 10Á5 and 9Á2 months, respectively. Univariate analysis for FFS1 and OS1 are summarized in Table II . PIT high-risk group at time of relapse was associated with shorter OS1 in both PTCL-NOS and AITL (both P < 0Á001). Neither pralatrexate nor romidepsin was associated with longer FFS1 compared to other therapies when used as second line therapy. Multivariate analysis incorporating second PIT risk factors at relapse, the duration of the response to first line therapy and eventual application of auto-SCT or allo-SCT revealed that use of pralatrexate at some point during the treatment was associated with significantly longer OS1 in patients with PTCL-NOS (HR: 0Á33, 95% CI: 0Á16-0Á65, P = 0Á001) and AITL (HR: 0Á39, 95% CI: 0Á16-0Á97, P=0Á044) ( Table III) . Use of romidepsin at any point during the treatment was not associated with longer OS1 in the patients with PTCL-NOS (HR: 1Á09, 95% CI: 0Á61-1Á97) and AITL (HR: 0Á99, 95% CI: 0Á53-1Á85) in multivariate analysis.
Results for patients undergoing SCT
Overall, 36 patients (18 PTCL-NOS, 18 AITL) underwent auto-SCT and 31 patients (20 PTCL-NOS, 11 AITL) underwent allo-SCT after progression/relapse. Among the 31 patients who underwent allo-SCT, five patients underwent auto-SCT as part or initial therapy and three for salvage. The median number of prior regimens prior to SCT was 2 (range, 2-6) and 61% of the patients underwent SCT after the second line regimen. The OS1 for patients who received SCT after second line regimen (first progression/relapse) and OS2 for patients who received SCT after third line regimen (second progression/relapse) were 33Á9 months (95% CI: 14Á0-67Á7 months) and 48Á4 months (95% CI: 8Á2 months-not reached), respectively. We did not observe a plateau of the survival curve in patients who received auto-SCT (Fig 3A) , although the causes of death after 4 years post auto-SCT were not lymphoma (myelodysplastic syndrome, infection and pancreatic cancer). In contrast, only one death (lymphoma) occurred more than 2 years after allo-SCT (Fig 3B) . The 5-year OS rates after auto-SCT and allo-SCT were 32% (95% CI: 15-50%) and 52% (95% CI: 32-68%), respectively, whereas the 5-year OS1 rates (after first progression/relapse) of patients who did not receive either SCT at any point during treatment was 10% (95% CI: 5-16%, Fig 3C) .
Discussion
The survival outcome of patients with PTCL-NOS and AITL after progression/relapse remains very poor, even with newer treatment options, and has not significantly changed since 1999. The median FFS and OS after progression/relapse for patients who did not proceed to SCT were 3Á0 and 8Á3 months, respectively, which are generally in keeping with the data from the British Columbia Cancer Agency and the Swedish Lymphoma Registry (Mak et al, 2013; Ellin et al, 2014) . In addition, we have shown that disease control becomes more difficult as patients experience multiple recurrences.
In order to obtain a comprehensive understanding of survival outcome after progression/relapse in patients with PTCL-NOS and AITL, we included the patients who proceeded to SCT in the analyses. Because of the retrospective nature of our study, we could not assess the actual impact of SCT on survival in patients who obtained responses to salvage treatment. Yet, it still seems reasonable to consider auto-SCT or allo-SCT for patients who experience good responses to salvage therapies, as these approaches were associated with up to 50% of the 5-year FFS rate. It should be noted that the survival curve of patients after auto-SCT continues to decline after 5 years, whereas the survival curve of patients who underwent allo-SCT reached a plateau at about 50% (Fig 3B) , probably due to graft-versus lymphoma effect. Our finding is similar to those of several other studies of allo-SCT for PTCL, showing three-to fiveyear survival rates that approach 40-50% (Le Gouill et al, 2008; Shustov et al, 2010; Jacobsen et al, 2011; Dodero et al, 2012; Kim et al, 2013) . The challenge of SCT is that these treatments are only available for limited numbers of patients who are relatively young and fit, who achieve good responses to the therapy and who have an available stem cell source. In fact, only 17% and 15% of the patients received auto-SCT and allo-SCT after progression/relapse, respectively. Better salvage treatment to achieve higher response rates to increase the number of patients who can proceed to SCT, better transplant strategies for elderly patients and ultimately, better treatments to achieve longer remission without SCT are needed to improve the survival outcome of patients with relapsed/refractory PTCL-NOS and AITL.
Pralatrexate and romidepsin have been approved by the FDA for treatment of relapsed/refractory PTCL. In a phase II study of pralatrexate for 115 patients with relapsed/refractory PTCL, the drug achieved an ORR of 29% with a CR rate of 11% (O'Connor et al, 2011) . The median PFS was 3Á5 months, with the median duration of response of 10Á1 months. In a phase II study for romidepsin for 130 patients with relapsed/refractory PTCL, the ORR was 25% with CR a rate of 15% (Coiffier et al, 2012) . The median PFS was 4 months, with the median duration of response of 28 months (Coiffier et al, 2014) . Our retrospective data are generally similar to those reported in these studies of romidepsin and pralatrexate. Interestingly, the use of pralatrexate at some point during the treatment was associated with a longer OS in multivariate analysis, for both patients with Overall, despite the limitation of retrospective analysis, our analysis provides a snapshot on survival outcomes for a large number of patients with relapsed/refractory PTCL-NOS 95% CI, 95% confidence interval; AITL, angioimmunoblastic T-cell lymphoma; HR, Hazard ratio; PIT, prognostic index for PTCL-NOS; PTCL-NOS, peripheral T-cell lymphoma-not otherwise specified. and AITL. Even with the recent approval of new drugs, there has been no significant improvement in survival for our patient cohort following progression/relapse since 1999. Further research is needed to better understand the biology of PTCL and to identify a patient population that is likely to benefit from targeted agents. Obviously, novel therapeutic approaches with higher efficacy and better safety profile are needed. 
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